CAR T-cell therapy for lung cancer and malignant pleural mesothelioma Journal Article

Authors: Zeltsman, M.; Dozier, J.; McGee, E.; Ngai, D.; Adusumilli, P. S.
Article Title: CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
Abstract: Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non–small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. One such approach being investigated is administration of tumor antigen-targeted T cells with transduction of a chimeric antigen receptor (CAR). CARs are synthetic receptors that enhance T-cell antitumor effector function and have gained momentum to investigate in solid tumors based on recent successes of clinical trials treating patients with B-cell hematologic malignancies. This review summarizes target antigens for CAR T-cell therapy that are being investigated in preclinical studies and clinical trials for both NSCLC and MPM patients. We discuss the rationale for combination immunotherapies for NSCLC and MPM patients. Additionally, we have highlighted the challenges and strategies for overcoming the obstacles facing translation of CAR T-cell therapy to solid tumors. © 2017 Elsevier Inc.
Journal Title: Translational Research
Volume: 187
ISSN: 1931-5244
Publisher: Elsevier Science, Inc.  
Date Published: 2017-09-01
Start Page: 1
End Page: 10
Language: English
DOI: 10.1016/j.trsl.2017.04.004
PROVIDER: scopus
PMCID: PMC5581988
PUBMED: 28502785
Notes: Review -- Export Date: 4 October 2017 -- Source: Scopus
Citation Impact
MSK Authors
  1. Daniel Ngai
    5 Ngai
  2. Erin Anne McGee
    5 McGee
  3. Jordan Michael Dozier
    8 Dozier